Merck’s Keytruda OK’d in China for 2nd-line esophageal cancer

China’s National Medical Products Administration has approved Merck’s (NYSE:MRK) Keytruda (pembrolizumab) for the treatment of patients with locally advanced/metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) as determined by a fully validated test, following failure of one prior line of systemic therapy.

In China, more than 90% of esophageal cancers are squamous cell carcinomas.

https://seekingalpha.com/news/3584810-mercks-keytruda-okd-in-china-for-2nd-line-esophageal-cancer